Best Kinase Inhibitor for perivascular epithelioid cell neoplasms
4 Kinase Inhibitor drugs indicated for perivascular epithelioid cell neoplasms, ranked by our independent rating. The current highest-rated is sirolimus. Compare them with all treatments for perivascular epithelioid cell neoplasms or the full Kinase Inhibitor class. Not medical advice — always consult a professional.
Top kinase inhibitor for perivascular epithelioid cell neoplasms: 1. Sirolimus · 2. Hyftor · 3. Rapamune
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Sirolimus | 62/100 | Prescription | $49 | View → |
| 2 | Hyftor | Not yet rated | Prescription | $49 | View → |
| 3 | Rapamune | Not yet rated | Prescription |
Full ranking · 4 drugs
Frequently asked
- What is the best kinase inhibitor for perivascular epithelioid cell neoplasms?
- By our independent rating, sirolimus currently ranks highest among Kinase Inhibitor drugs used for perivascular epithelioid cell neoplasms. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which kinase inhibitor drugs treat perivascular epithelioid cell neoplasms?
- pharmaranks lists 4 Kinase Inhibitor products indicated for perivascular epithelioid cell neoplasms, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.